Journal of Cystic Fibrosis

Article	Citations
P402 Separation anxiety or a Kaftrio side effect? Implementation of cognitive behavioural therapy strategies with a young child with cystic fibrosis (CF): A clinical case study	347
P408 The halo effect in cystic fibrosis: when educated patients in turn educate their family carers	139
EPS10.07 Exacerbation characteristics and clinical outcomes in the elexacaftor/tezacaftor/ivacaftor era: same-same but different?	125
WS08.03 How does elexacaftor/tezacaftor/ivacaftor affect improvement in exercise capacity and body composition in adults with cystic fibrosis who have completed an exercise intervention?	121
P131 Effect of deprescribing from inhaled corticosteroids in people with cystic fibrosis: challenges & opportunities for a target trial emulation using the UK CF Registry	115
P296 Characteristics of carbohydrate metabolism disorders in children with cystic fibrosis in the Moscow region	103
P109 Safety of elexacaftor/tezacaftor/ivacaftor in patients 6 through 18 years with cystic fibrosis and at least one F508del allele: a retrospective Italian multicenter study	94
WS13.03 Anti-inflammatory effects of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis heterozygous for F508del	88
EPS10.06 Highly-effective CFTR modulation is associated with greater height and peak lung function in children with cystic fibrosis	82
P172 Oscillometry: assessment of bronchial obstruction in children with cystic fibrosis	77
EPS8.02 Evolving physiotherapy airway clearance technique (ACT) interventions during cystic fibrosis (CF) pregnancy in the variant specific therapy (VST) era	77
P078 Hyperacute response to cystic fibrosis transmembrane conductance regulator modulation	75
P227 Life threatening infection with a highly resistant Achromobacter xylosoxidans strain	72
P024 Analysis of the effect of cytochrome P450 genes polymorphism on the efficacy and safety of CFTR modulator therapy in cystic fibrosis	70
P478 Multiple breath inert gas wash out in infants and toddlers with cystic fibrosis before and after initiating inhaled hypertonic saline	68
564 “How do you live the best life you can with this pain?” A qualitative study of the challenges of living with CF and pain in the modulator era	65
209 Inositol-requiring enzyme 1β is a therapeutic target for cystic fibrosis airway muco-obstructive disease	64
235 Differential regulation of immune function by highly effective CFTR modulators in THP-1-derived macrophages	64
184 Bioengineered three-dimensional cystic fibrosis lung airway model for drug testing	60
808 Implementation of physical therapy and exercise education in annual cystic fibrosis clinic	58
260 RCT2100 rescue of cystic fibrosis (CF) transmembrane conductance regulator function in CF human bronchial epithelial cells and mucociliary clearance in CF ferrets	58
39 Using mouse models to understand the critical roles of granulocyte macrophage colony stimulating factor and macrophages for control of pulmonary Mycobacterium abscessus infection	57
365 Differential effects of (S)- and (R)-vanzacaftor on BKCa potentiation and CFTR correction	53
27 Standing up to the “bully”: Staphylococcus aureus can sustain long-term infection in the presence of Pseudomonas aeruginosa and may outcompete in the cystic fibrosis airway	51
99 Development and validation of a deep neural network to predict antimicrobial resistance in people with cystic fibrosis using routinely collected electronic healthcare record data	51

490 What are the experiences of cystic fibrosis clinical nurse specialists? Are systemic practice ideas unknowingly incorporated when working with children and families?	50
304 Assessing a novel dual-endonuclease system in restoring CFTR expression in cystic fibrosis humanized mouse and human airway models	47
526 Non-surgical management of urinary incontinence in women with cystic fibrosis	46
320 Gain-of-function CFTR mutation improves function of W1282X CFTR	46
558 Challenges faced by parents of children with cystic fibrosis in Ireland: The Irish Comparative Outcome Study of Cystic Fibrosis	46
644 Timely initiation of pancreatic enzyme replacement therapy for surgical cystic fibrosis infants in the neonatal intensive care unit	44
529 Are adults with cystic fibrosis choosing to continue with airway clearance therapy in the era of highly effective gene modulator therapy?	44
586 Description of a novel therapeutic support group for siblings of children with cystic fibrosis: Siblings Supporting Others and Achieving Resilience	44
773 A quality improvement project to improve the evaluation of low bone density in people with cystic fibrosis	42
480 Weight stigma among healthcare professionals treating CF in North America	39
Restoring airway epithelial homeostasis in Cystic Fibrosis	39
Improved early growth in Danish children with cystic fibrosis from 2000-2022	39
European survey of newborn bloodspot screening for CF: opportunity to address challenges and improve performance	36
WS13.01 The cystic fibrosis Home Sputum-Induction Trial (CF-HomeSpIT - ISRCTN86523335) to evaluate home sputum-induction and early morning saliva sampling in children with cystic fibrosis	36
Autoimmunity in people with cystic fibrosis	35
Contents	35
Evidence for secondary ciliary dyskinesia in patients with cystic fibrosis	34
WS15.05 Improvements in structural lung disease in people with CF aged 12 and above on elexacaftor/tezacaftor/ivacaftor are sustained for up to two years	34
78 Pseudomonas aeruginosa induced GM-CSF production by airway epithelial cells could help protect against Mycobacterium abscessus	33
325 Evaluation of CFTR gene editing efficacy using patient-derived nose- on-chip model	32
227 Nascent chain misfolding slows translation and stimulates co- translational mRNA decay	31
97 Separability of membrane permeabilization and cell killing activities of the human host defense peptide LL-37 in Pseudomonas aeruginosa	30
203 Airway dysanapsis is associated with residual pulmonary exacerbation risk in children with cystic fibrosis treated with elexacaftor/tezacaftor/ ivacaftor	30
523 Navigating school with cystic fibrosis: perspectives of people with CF and their caregivers	29
41 Loss of MexEF-OprN function increases virulence of clinical Pseudomonas aeruginosa isolates	29
346 Leaky gut, dysbiosis, and inflammation support inter-organ communication in cystic fibrosis	29
748 Development of metabolic syndrome in people with cystic fibrosis after three years of elexacaftor/tezacaftor/ivacaftor	29
258 Functional correction of CFTR-G542X in human bronchial epithelial cells using a Type I CRISPR adenine base editor with a guide-length- tunable editing window	29
634 Evaluating shared decision making in lung transplant discussions between clinicians and people with severe CF	29
729 Impact of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on healthcare resource utilization (HCRU) over three years in LONGITUDE – a UK CF Registry observational study	28
379 Identifying and prioritizing burdens of cystic fibrosis care for Canadians living with CF	28
241 Functional characterization of an ex vivo ferret model as a precursor for cell therapy	27
757 The impacts of highly effective modulator therapy and telehealth on cystic fibrosis care: Changes in visit frequency	27
786 Use of aerobic exercise for airway clearance in a pediatric CF care center	26
279 Simultaneous inhibition of DNA-PKcs and 53BP1 enables the enrichment-free replacement of the CFTR cDNA in airway basal stem cells	26
496 Pilot and feasibility study of an individualized telehealth exercise program in CF patients	26
48 Small airway epithelial cells in M. abscessus infection: Implications for inflammation and epithelial barrier integrity	26
475 Physiologically based pharmacokinetic of elexacaftor/tezacaftor/ ivacaftor in children with cystic fibrosis: extrapolation of the dosing regimen in children under 2 years of age	26
22 The changing face of cystic fibrosis research: challenges of multi-centre microbiology cohort studies	25
652 Proteomics of bronchoalveolar lavage fluid in cystic fibrosis ferrets spontaneously colonized by Pseudomonas aeruginosa	25
34 Regulation of an epoxide-based virulence factor in Pseudomonas aeruginosa	24
P081 Elezacaftor/tezacaftor/ivacaftor therapy and quality of life in children and their caregivers	24
P052 Introduction of an innovative “pill-swallowing school” in a cystic fibrosis paediatric population within a tertiary centre	24
252 Model systems to define tool LNP vehicles for the development of next generation therapies for Cystic Fibrosis	24
P104 CF-AMR Syndicate Collaborative Discovery Programme to accelerate the development of antimicrobials to treat lung infections in cystic fibrosis	24
165 IL-21 and IL-21R interaction plays a key role in mounting humoral and cell-mediated immune response to adenoviral and adeno-associated viral vectors in lung	24
P352 Effect of ACE, ACTN3, PPARA, PPARGC1A gene polymorphisms on nutritional status in patients with cystic fibrosis in the Russian Federation	24
WS10.02Proteomic analysis of nasal lavage fluid and sputum samples in people with cystic fibrosis during 24 months of treatment with elexecaftor/tezacaftor/ivacaftor - The RECOVER study	23
P174 A retrospective review of lung ultrasound in guiding physiotherapy input for people with cystic fibrosis in an in-patient setting	22
P223 The role of horizontal Gene transfer in the development of resistance in Achromobacter ruhlandii	22

WS14.01Primary nasal epithelial cells for personalized medicine in non-eligible cystic fibrosis patients	22
P118 Community engagement and involvement in clinical trials and beyond…	22
P341 Body composition and handgrip strength among children and adolescents with cystic fibrosis: correlation with anthropometric parameters and disease severity	22
P159 Long COVID in people with cystic fibrosis: a prospective observational study within the Italian Cystic Fibrosis Society	22
P278 Trends in paediatric bone mineral density 2016-2024 – a single centre study	22
P033 The impact of newborn bloodspot screening program modification in 2023 on the time of diagnosis in cystic fibrosis patients and follow-up care	21
P418 Recalibrating “a whole new life”: exploring the impact of elexacaftor/tezacaftor/ivacaftor on self-concept for adults with cystic fibrosis	21
P421 Accessing impact of elexacaftor/tezacaftor/ivacaftor therapy on antidepressant usage in an adult cystic fibrosis population	21
P046 Investigating the safety of elexacaftor/tezacaftor/ivacaftor exposure during early development	21
P308 Effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycaemic control in children with cystic fibrosis: a promising trend towards improved glucose regulation	21
ePS2.02 Comparison of FEV on a remote spirometry device with hospital software in an adult cystic fibrosis cohort	20
P249 Aspergillus fumigatus prevalence in Georgian paediatric cystic fibrosis patients	20
257 Rapid health decline in young cystic fibrosis transmembrane conductance regulatorG551D ferrets after discontinuation of cystic fibrosis transmembrane conductance regulator modulator	20
P029 Antisense oligonucleotide-based drug development for cystic fibrosis patients carrying the 2789+5 G-to-A splicing mutation	20
P209 Physical fitness and habitual physical activity in children with cystic fibrosis - do they improve with elexacaftor/tezacaftor/ivacaftor therapy?	19
WS03.03 Qualitative analyses of the experiences of people with end-stage cystic fibrosis lung disease receiving ELX/TEZ/IVA	19
P083 Decreased respiratory burst in circulating neutrophils after initiation of CFTR modulator therapy in cystic fibrosis patients with chronic lung infections	19
P143 Bronchopulmonary infection/colonisation in Spanish cystic fibrosis patients: preliminary results of a multicentre study	19
WS11.04 Confirmatory genetic testing for all cystic fibrosis screen positive newborns: a 12-year analysis	19
WS11.03 Repeated sweat testing in children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID)	19
ePS3.05 Induced levofloxacin resistance persists in evolved lineages of Pseudomonas aeruginosa isolates from people with cystic fibrosis after exposure to other inhaled antibiotics	19
ePS4.03 Outcomes of COVID-19 in patients with cystic fibrosis in Wales, UK	18
P221 Tension-free vaginal tape – a 15-year review of effect on urinary incontinence in patients with cystic fibrosis	18
P106 Upper airway disease in adults with cystic fibrosis: a cross-sectional study	18
WS10.03 Impact of triple CFTR modulator therapy on urinary incontinence symptoms in adults with cystic fibrosis	18
145 Prescription of elexacaftor/tezacaftor/ ivacaftor in lung transplant recipients with cystic fibrosis	18
447 Mucociliary interactions and the vertical clearance assay 2.0	18
341 Improving care for pregnant people with cystic fibrosis by increasing knowledge of obstetric providers	17
487 Evaluating use of doxycycline versus vancomycin for treatment of methicillin-resistant Staphylococcus aureus–associated acute pulmonary exacerbations in people with cystic fibrosis	17
332 Vocational rehabilitation services for people with cystic fibrosis: Predictors of employment outcomes	17
59 Improving mycobacterial sputum culture collection in adult patients during the highly effective modulator therapy era	17
P360 Mental health in cystic fibrosis patients: predictive factors and psychopathology	17
P282 Implementing routine assessment of gastrointestinal outcome measures in the cystic fibrosis clinic	17
51 Outcomes after SARS-CoV-2 infection in Canadians with cystic fibrosis: Analyses using the Canadian Cystic Fibrosis Registry	17
132 Respiratory symptom changes during menstrual cycles in women with cystic fibrosis	17
P243 The effect of hypoxic conditions on Burkholderia cenocepacia clinical isolates from individuals with cystic fibrosis	17
P418 Patient satisfaction and clinical effectiveness of using the I-neb in children with cystic fibrosis (CF) in Wales	17
419 Role of macrophage cystic fibrosis transmembrane conductance regulator in lung inflammation	17
348 Single-cell multi-omics profiling reveals novel regulatory networks of CFTR in the kidney	16
329 Intrinsic conformational dynamics required for CFTR gating cycle revealed by single-molecule Förster resonance energy transfer	16
P007 Experience of using intestinal current measurement (ICM) in Russia	16
P387 Reviews and outcomes from a new pregnancy support service at a large cystic fibrosis centre	16
633 Extracellular vesicles as delivery vectors to enhance killing of bacteria and viruses by airway-recruited human neutrophils	16
249 Pharmacological rescue of CFTR premature termination codon mutations by novel small molecules	16
WS19.01 Non-adherence in the twilight zone: the complexity of complex medications	16
P295 The results of colorectal cancer screening in patients with cystic fibrosis in Wales	16
100 Vancomycin demonstrates activity against Mycobacterium abscessus in combination with guideline-recommended antibiotics under physiologically relevant stress conditions	15
P382 Cystic fibrosis and disordered eating behaviour: a collaborative approach to improve care	15
624 Evaluating precision medicine tools in cystic fibrosis for racial and ethnic fairness	15
P017 The role of the VDR gene in the formation of clinical manifestations and complications in cystic fibrosis	15
P104 The dynamics of health of children with cystic fibrosis in Russian Federation according to the registry data during last 10 years	15
P169 Vitamin absorption after the introduction of elexacaftor/tezacaftor/ivacaftor in children and adolescents diagnosed with cystic fibrosis	15
43 Bacteriophages that kill Pseudomonas aeruginosa induce heterogenous cellular responses in the airway epithelium	15
647 Impact of newborn screening program with NextGen sequencing on direct patient care	15
WS06.03 A real-world evaluation of remote monitoring in cystic fibrosis care: a mixed-methods multicentre observational study	15
558 Development of a gene editing strategy to treat cystic fibrosisassociated liver disease	15
417 Resolvin D1 reduces cystic fibrosis lung disease and inflammation associated with mucus obstruction	15
P134 Evaluation of multidisciplinary ambulatory care cost among children with cystic fibrosis: a comparative study between cystic fibrosis centers in Ireland and the United States	15
260 Cystic fibrosis transmembrane conductance regulator modulator–associated liver inflammation in pediatric cystic fibrosis	15
54 Recombinant pyocins as emerging therapies against respiratory infections with Pseudomonas aeruginosa	14
679 Effect of hybrid closed loop insulin delivery on glycemic control in adolescents and adults with cystic fibrosis-related diabetes	14
491 The Cystic Fibrosis Questionnaire–Revised and body image in adults in the era of elexacaftor-tezacaftor-ivacaftor	14
11 Examining antibiotic regimen spectrum and clinical outcomes of pulmonary exacerbation treatment	14
410 Multidisciplinary collaboration for transition readiness and planning	14
Neurovascular complications post bronchial artery embolisation in patients with cystic fibrosis. A 7-year single centre retrospective review	14
13 Extended-interval dosing of amikacin against Mycobacterium abscessus reduces efficacy in vitro	14
P219 Otorhinolaryngologic, audiological and genetic findings in children with cystic fibrosis: a tertiary care experience	14
314 A role for CFTR in pancreatitis	14
524 Acid suppression therapy and associations with growth, gut microbiome, and early-onset lung disease in young children with cystic fibrosis	14
292 Mechanism of CFTR modulation on endothelial mechanosensitive channels	14
288 CFTR genetic variants and association with cancer	14
291 Development and validation of the Cystic Fibrosis Stress Questionnaire: A cystic fibrosis–specific measure of perceived stress	13
“Mind the gap”- will we ever see equal median predicted survival for males and females in cystic fibrosis?	13
Rethinking CFTR variant responsiveness: Differential responses to vanzacaftor and elexacaftor	13
Clinical efficacy of CFTR modulator therapy in people with cystic fibrosis carrying the I1234V mutation	13
372 Cystic fibrosis does exist in India! A successful approach to education and improving awareness of cystic fibrosis of physicians and caregivers in India	13
EPS5.08 Elexacaftor/tezacaftor/ ivacaftor reduces need for pancreatic enzymes, enteral feeding and omeprazole use without causing excessive weight gain: a 2-year observational study	13
Theranostics vs theratyping or theranostics plus theratyping?	13
462 Cystic fibrosis mental health and wellness questionnaire—factors and properties	13
Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas	13

Structure basis of CFTR folding, function and pharmacology	13
The diagnostic challenge of pancreatic cysts in patients with cystic fibrosis: a case series and review of the literature	13
Bone health after 3 years of ETI therapy: a real-world study from the Danish cystic fibrosis cohort	12
Using heart rate data from wrist worn activity trackers to define thresholds for moderate to vigorous physical activity in children and young people with cystic fibrosis	12
P462 Applicability of A-STEP performance test in patients diagnosed with cystic fibrosis in Turkish population	12
ePS2.04 Is tele-physiotherapy as effective as home-visit-guided physiotherapy among children with cystic fibrosis?	12
Long-term outcomes in people with CF lacking FEV1 response to elexacaftor/tezacaftor/ivacaftor therapy	12
P379 TIDES 2.0: prevalence and longitudinal course of depression, anxiety, and behaviour problems in children with cystic fibrosis (CF) under 12 years of age	12
Characteristics associated with cystic fibrosis-related pulmonary exacerbation treatment location	12
Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor	12
P460 Assessing the exercise capacity of adolescents with cystic fibrosis in the post elexacaftor/tezacaftor/ivacaftor era, via cardiopulmonary exercise test	12
CFTR-beyond the airways: Recent findings on the role of the CFTR channel in the pancreas, the intestine and the kidneys	12
Contents	12
Treatment of intestinal and liver features in cystic fibrosis mice by the osmotic laxative polyethylene glycol	12
Sexual and reproductive health experiences and care of adult women with cystic fibrosis	12
Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort	12
693 Machine learning analysis of continuous glucose monitoring after elexacaftor/tezacaftor/ivacaftor initiation in young children predicts dysglycemia better than an oral glucose tolerance test	12
Treatment decision-making for using CFTR modulator therapy in patients with cystic fibrosis	12
P357 Effect of elexacaftor/tezacaftor/ivacaftor on metabolic parameters and body weight in patients with cystic fibrosis: a five case series with oneyear follow-up	11
WS08.04 Assessment of functional exercise capacity using telehealth: reliability, validity, and usability in children with cystic fibrosis	11
P262 Lack of association between antibiotic regimen spectrum and pulmonary exacerbation treatment responses	11
P306 Analysis risk factors for the decrease bone mineral density in cystic fibrosis	11
P424 Totally implantable venous access devices (TIVADs) flushing intervals: where are we?	11
P125 Development of a holistic feedback package to support quality improvement in cystic fibrosis centres in the UK	11
P229 Do CFTR modulators interfere with microbiological diagnosis?	11
P316 Increasing numbers of pregnancies due to modulator therapy in cystic fibrosis	11
P363 A retrospective review of fat-soluble vitamins A, D and E levels and vitamin supplementation in a cystic fibrosis (CF) maternal health population	11
P258 Development of a liquid polymicrobial biofilm model for preclinical testing of novel cystic fibrosis therapeutics	11
P236 Investigating the impact of elexacaftor/tezacaftor/ivacaftor therapy on longitudinal oropharyngeal microbiome dynamics in children with cystic fibrosis	11
P280 Rapid review of the outcome measures and endpoints used to measure gastrointestinal disease in cystic fibrosis (CARDS-CF study)	11
P052 Real-life experience with a generic formulation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and responsive CFTR variants with previous modulators therapy	11
P359 The impact of elexacfator/tezacaftor/ivacaftor on the weight trajectories of children and adolescents and predictive factors	11
Contents Page	11
EPS10.10 Elexacaftor/tezacaftor/ivacaftor remains inaccessible for people with cystic fibrosis in low- and middle-income countries: how can this be solved?	11
P323 Gastrointestinal health through self-reported assessment in children with cystic fibrosis	10
WS05.04 SPL84 efficient and durable effect, restoring 3849 +10 kb C-to-T mutated CFTR, when treated through the apical side of primary HBE cells	10
551 Integration of psychosocial screening tool into routine care of children with CF: Results of a 1-year pilot study and lessons learned	10
489 Journey mapping of barriers to transitioning to adult CF care	10
207 Enhancing apical loop currents in airway epithelia carrying minimal function CFTR mutations	10
182 IL-21R and IL-21 play a crucial role in modulating B and T cell immune responses to viral gene therapy vectors in the lungs	10
49 Differential effects of cationic antimicrobials on intrinsic antibiotic resistance in Pseudomonas aeruginosa	10
65 Thymic stromal lymphopoietin and IL-33 alarmin cytokine production by primary human cystic fibrosis lung macrophages is induced by infection with Pseudomonas aeruginosa and further increased by CFT	10
513 Elexacaftor/tezacaftor/ivacaftor dose reduction leads to resolution of clinical adverse events without a significant effect on sweat chloride or FEV1	10
P275 Utility of adding gamma-glutamyl transpeptidase to platelet ratio to cystic fibrosis related liver disease screening	10
470 Implementing annual collection of self-reported patient demographic information	10
87 Activity of β-lactams and new β-lactamase inhibitors in multidrug-resistant Burkholderia contaminans	10
211 Characterization of airway submucosal gland hypertrophy in cystic fibrosis	10
233 Altered role of septins in Pseudomonas aeruginosa intracellular infection of cystic fibrosis bronchial epithelial cells	10
607 Evidence of protease dose-response in a Phase 1 trial of ANG003, a non-porcine pancreatic enzyme replacement therapy	10
183 Adenylate cyclase 6 is required for cyclic adenosine monophosphate–dependent activation of CFTR to regulate mucociliary clearance in cystic fibrosis airways	10
45 Development of a co-culture model for secondary screening of candidate anti-microbial compounds targeting persistent lung infections in cystic fibrosis	10
330 Rescue of CFTR nonsense mutations is enhanced under inflammatory stimuli	10
P123 Establishing a cystic fibrosis learning network for low and middleincome countries	10
326 Generation of a robust CFTR-specific immunolabeling protocol	10
469 Impact of social complexity on long-term health outcomes and survival in young adults with cystic fibrosis	10
680 Effects of elexacaftor/tezacaftor/ivacaftor on growth and puberty in children with cystic fibrosis	10
716 Pilot screening prediction model for late-diagnosed cystic fibrosis	10
636 Characterizing use of acid-suppressing medications and foregut gastrointestinal testing in advanced cystic fibrosis lung disease in cystic fibrosis centers	10
628 Esophagogastroduodenoscopy findings in adults with cystic fibrosis: implications for screening and management	10
P099 The London CTAP network standard operating procedure for averting medications prohibited during clinical trials in cystic fibrosis	10
394 Elexacaftor/tezacaftor/ivacaftor interferes with hippocampal neurotransmission in mice	9
403 Exploring CFTR variants: implications for exocrine pancreatic diseases	9
865 Elexacaftor/tezacaftor/ivacaftor concentrations are similar in transplanted and non-transplanted people with CF	9
4 Within-lung interspecies gene transfer causes rapid evolution of extreme antibiotic resistance in cystic fibrosis	9
P274 Muddying the waters with menopause! How important is addressing the menopause in terms of cystic fibrosis care: Antibiotics or hormone replacement therapy?	9
WS07.01‘Silent' lung disease progression in people receiving elexacaftor/tezcaftor/ivacaftor (ETI) therapy revealed by Oxygen Enhanced-MRI (OE-MRI) and Multiple breath washout with Short extension (MB	9
EPS2.06Exploring the diversity of nontuberculous mycobacteria in cystic fibrosis centers across the U.S.: Lessons from the prospective HALT study	9
650 Single-center cohort study evaluating quality of colonoscopy bowel preparation in adults with cystic fibrosis	9
38 ACE-1b, a novel anti-infective conjugated electrolyte, effectively controls nontuberculous mycobacterial infections	9
817 Harnessing the power of the electronic medical record to implement the new cystic fibrosis liver disease guidelines	9
309 Pulmonary ionocytes regulate chloride secretion and absorption via CFTR	9
P453 A study on patient and healthcare provider experiences with outpatient sexual and reproductive healthcare for adults with cystic fibrosis: insights from a single-center study	9
P163 The role of pharmacists in cystic fibrosis care: preliminary results from a systematic review	9
P439 The role of the Research Play Specialist in CF Clinic, helping children and adolescents to develop coping strategies to overcome some of their anxieties in relation to blood sampling and beyond	9
75 Improvements in nutritional status, lung function, and respiratory cultures in pediatric cystic fibrosis after starting elexacaftor/tezacaftor/ivacaftor therapy: A real-world, multicenter study	9
344 Transgene expression and CFTR channel function in human bronchial epithelial cells after addition of CFTR modulators and 4D-710	9
308 Ligand-free biodegradable poly(beta-amino ester) nanoparticles for targeted systemic delivery of mRNA to the lungs	9
P345 Increasing prevalence of pancreatic sufficiency in a paediatric CF unit – are CFTR modulators the cause?	9
P333 Scoping review protocol: Diet composition and quality in children with cystic fibrosis in the modulator era	9
EPS1.05Sleep quality and mental health in children with cystic fibrosis: the impact of elexacaftor/tezacaftor/ivacaftor therapy	9
552 Using the TriNetX database to describe the prevalence of VTE and gastrointestinal disease in children with cystic fibrosis	8
1 High Ca++ does not hinder cyclic diguanosine monophosphate–mediated control of the Pseudomonas aeruginosa biofilm life cycle	8
339 Diagnostic dilemmas in cystic fibrosis screen–positive infants with F191V and low sweat chloride	8
414 National patterns of CF RISE uptake and engagement: a multidimensional approach to increase transition program utilization	8
49 Bacterial siderophores drive cefiderocol resistance and crossprotection	8
72 Investigating polymicrobial interactions involving Streptococcus in the cystic fibrosis airway	8
536 Effect of elexacaftor-tezacaftor-ivacaftor on nutritional status and glucose metabolism in children and adolescents with cystic fibrosis	8
412 Increasing the number of people with cystic fibrosis seen in outpatient clinic quarterly	8
344 Unraveling the complexity of cystic fibrosis: genetic modifiers and their roles in cystic fibrosis pathogenesis	8
266 Airway clearance therapy: experiences and perceptions of adults with cystic fibrosis	8
239 Organoid-guided synergistic treatment of minimal function CFTR mutations with CFTR modulators, roflumilast and simvastatin: A personalized approach	8
Immunosuppressant management upon elexacaftor/tezacaftor/ivacaftor initiation in cystic fibrosis patients with prior liver transplant	8
Manifestation and staging of arthropathy in cystic fibrosis. Defining different stages of cystic fibrosis arthropathy using ultrasound imaging and clinical scoring	8
P299 Assessing dynamics of abdominal symptoms during a new therapy with elexacaftor/tezacaftor/ivacaftor using the new CFAbd-day2day© questionnaire	8
102 Clinical Pseudomonas aeruginosa isolates from cystic fibrosis sinusitis prevent flagellin-mediated immune recognition	8